Sirtex (ASX: SRX)

On the 17/3/15 Sirtex Medical released to the market their long awaited SIRFLOX trail results. At a glance, they noted that

1) SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival. And;
2) SIRFLOX study does show a statistically significant improvement in Progression-Free Survival.

From my personal analysis 1) essentially says that SIR-Spheres in conjunction with Chemo does not improve ones overall PFS. However, 2) reinforces what the product was designed to do.

In the act of prudence, i locked in a sizable portion of my holdings a few days prior to the announcement for $39.10 per share (realising a capital appreciation of roughly 90%). This was entirely done to protect the downside.

To be continued...